Skip to main content

Table 2 Efficacy of traditional NSAIDs or iCOX2 vs. placebo in patients with axial spondyloarthritis: meta-analyses of randomized clinical trials

From: Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis

  TRADITIONAL NSAIDs
n=1289
iCOX2
n=669
PAIN VAS (95% CI) −16.75 (−20.28 to −13.07) −21.68 (−35.94 to −7.42)
PGA −17.75 (−24.39 to −11.10) −20.82 (− 39.88 to −11.75)
ASAS20 60% vs. 23% (PbO)
RR=2.49 (1.94 to 3.19)
57% vs. 20% (PbO)
RR=2.51 (1.66 to 3.79)
BASFI −9 (− 13 to −5) −13.4 (− 17.3 to −5)
MS - SMD −0.4 (−0.58 to −0.22) NA
CRP mg/L −3.37 (−6.11 to − 0.62) NA
PAIN50% 48% vs 21%
2.25 (1.75 to 2.89)
NA
  1. NSAIDs nonsteroidal anti-inflammatory drugs, iCOX2 COX-2-selective inhibitors, PAIN VAS pain by visual analog scale 0–100 mm, PGA Patient Global Assessment 0–100 mm, BASFI Bath Ankylosing Spondylitis Function Index 0–100 mm, MS-SMD standardized mean difference in the duration of morning stiffness, CRP C-reactive protein, PAIN50% ≥ 50% improvement in pain, RR relative risk, PbO placebo, N/A meta-analysis not feasible